Preferred Name |
niacin |
|
Synonyms |
3-Pyridinecarboxylic Acid |
|
Definitions |
A water-soluble vitamin belonging to the vitamin B family, which occurs in many animal and plant tissues, with antihyperlipidemic activity. Niacin is converted to its active form niacinamide, which is a component of the coenzymes nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. These coenzymes play an important role in tissue respiration and in glycogen, lipid, amino acid, protein, and purine metabolism. Although the exact mechanism of action by which niacin lowers cholesterol is not fully understood, it may act by inhibiting the synthesis of very low density lipoproteins (VLDL), inhibiting the release of free fatty acids from adipose tissue, increasing lipoprotein lipase activity, and reducing the hepatic synthesis of VLDL-C and LDL-C. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C689" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C689" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038351 |
|
altLabel |
3-Pyridinecarboxylic Acid Vitamin B3 nicotinic acid |
|
CAS Registry |
59-67-6 |
|
cui |
C0027996 C0028027 |
|
Date last modified |
2008-09-22 |
|
definition |
A water-soluble vitamin belonging to the vitamin B family, which occurs in many animal and plant tissues, with antihyperlipidemic activity. Niacin is converted to its active form niacinamide, which is a component of the coenzymes nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. These coenzymes play an important role in tissue respiration and in glycogen, lipid, amino acid, protein, and purine metabolism. Although the exact mechanism of action by which niacin lowers cholesterol is not fully understood, it may act by inhibiting the synthesis of very low density lipoproteins (VLDL), inhibiting the release of free fatty acids from adipose tissue, increasing lipoprotein lipase activity, and reducing the hepatic synthesis of VLDL-C and LDL-C. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C689" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C689" NCI Thesaurus) |
|
Legacy PDQ ID |
1097 |
|
NCI ID |
C689 |
|
notation |
CDR0000038351 |
|
NSC Code |
169454 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
niacin |
|
tui |
T109 T127 T121 |